44O Updated results from a phase I study evaluating the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC

作者：C.I. Rojas, Iwona Ługowska, Rosalyn A. Juergens, Adrian G. Sacher, Susanne Weindler, Mehmet Alı Nahıt Şendur, Rafał Dziadziuszko, Abhijit Pal, Eduardo Castañón Álvarez, E.S. Ahern, Nehal J. Lakhani, Li‐Chia Chen, Thomas Jemielita, Song‐Yi Choi, Anastasios Stathis · 发表于：ESMO Open · 年份：2024 · DOI：10.1016/j.esmoop.2024.102273 · 被引用次数：13 · 研究领域：Colorectal Cancer Treatments and Studies、Cancer, Hypoxia, and Metabolism、Cancer Treatment and Pharmacology

We present updated results from a phase 1 dose-escalation study (NCT05067283) of selective KRAS G12C inhibitor MK-1084 as monotherapy in advanced solid tumors and in combination with pembrolizumab (pembro) for first-line metastatic NSCLC.